Literature DB >> 3393943

Multiple myeloma: infectious complications.

K B Doughney1, D M Williams, R L Penn.   

Abstract

We review a ten-year experience in treating 60 patients with multiple myeloma. Infectious episodes occurred in 33 patients. Urinary tract infections caused by gram-negative organisms were the most frequent infections, and most of these were the result of catheterization. Pneumonia due to Streptococcus pneumoniae was encountered infrequently. This series confirms the emergence of gram-negative bacilli as the predominant pathogens in patients with multiple myeloma, and emphasizes the risk of instrumentation in these patients.

Entities:  

Mesh：

Year:  1988        PMID： 3393943     DOI： 10.1097/00007611-198807000-00012

Source DB:  PubMed          Journal:  South Med J        ISSN： 0038-4348            Impact factor:   0.954


  5 in total

Review 1.  Immune deficiencies in chronic lymphocytic leukemia and multiple myeloma.

Authors:  A Winkelstein; P S Jordan
Journal:  Clin Rev Allergy       Date:  1992 Spring-Summer

2.  Oral antibiotic prophylaxis of early infection in multiple myeloma: a URCC/ECOG randomized phase III study.

Authors:  D H Vesole; M M Oken; C Heckler; P R Greipp; M S Katz; S Jacobus; G R Morrow
Journal:  Leukemia       Date:  2012-05-08       Impact factor: 11.528

Review 3.  Multiple myeloma presenting with Hemophilus influenzae septic arthritis: case report and review of the literature.

Authors:  V Berthaud; J Milder; W el-Sadr
Journal:  J Natl Med Assoc       Date:  1993-08       Impact factor: 1.798

4.  Infections in patients with multiple myeloma treated with conventional chemotherapy: a single-center, 10-year experience in Pakistan.

Authors:  Mohammad Faizan Zahid; Natasha Ali; Myra Nasir; Maria Haider Baig; Mustafa Iftikhar; Syed Usman Bin Mahmood; Arhama Malik; Sara Atif; Mohammad Asim Beg
Journal:  Hematol Transfus Cell Ther       Date:  2019-06-14

5.  Levofloxacin prophylaxis in patients with newly diagnosed myeloma (TEAMM): a multicentre, double-blind, placebo-controlled, randomised, phase 3 trial.

Authors:  Mark T Drayson; Stella Bowcock; Tim Planche; Gulnaz Iqbal; Guy Pratt; Kwee Yong; Jill Wood; Kerry Raynes; Helen Higgins; Bryony Dawkins; David Meads; Claire T Hulme; Irene Monahan; Kamaraj Karunanithi; Helen Dignum; Edward Belsham; Jeff Neilson; Beth Harrison; Anand Lokare; Gavin Campbell; Michael Hamblin; Peter Hawkey; Anna C Whittaker; Eric Low; Janet A Dunn
Journal:  Lancet Oncol       Date:  2019-10-23       Impact factor: 41.316
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.